NASDAQ:FLGT - Fulgent Genetics Stock Price, Forecast & News

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics Inc (NASDAQ:FLGT) issued its quarterly earnings data on Monday, November, 4th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.08. The business earned $10.35 million during the quarter, compared to analyst estimates of $8.48 million. Fulgent Genetics had a negative return on equity of 0.16% and a negative net margin of 3.52%. View Fulgent Genetics' Earnings History.

Fulgent Genetics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Fulgent Genetics.

2 analysts have issued 12 month price objectives for Fulgent Genetics' stock. Their forecasts range from $12.30 to $12.30. On average, they expect Fulgent Genetics' share price to reach $12.30 in the next twelve months. This suggests that the stock has a possible downside of 11.3%. View Analyst Price Targets for Fulgent Genetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulgent Genetics.

News stories about FLGT stock have been trending extremely negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fulgent Genetics earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Fulgent Genetics.

Fulgent Genetics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 289,700 shares, an increase of 33.2% from the December 15th total of 217,500 shares. Based on an average trading volume of 311,500 shares, the short-interest ratio is currently 0.9 days. Approximately 3.7% of the shares of the stock are sold short. View Fulgent Genetics' Current Options Chain.

Some companies that are related to Fulgent Genetics include CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), OpGen (OPGN) and Cancer Genetics (CGIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), Baidu (BIDU), Baozun (BZUN), NVIDIA (NVDA), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Innovative Industrial Properties (IIPR), InVitae (NVTA) and TENCENT HOLDING/ADR (TCEHY).

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Raymond James Trust N.A. (2.24%), Wedge Capital Management L L P NC (0.46%) and Calamos Advisors LLC (0.27%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Raymond James Trust N.A.. View Insider Buying and Selling for Fulgent Genetics.

FLGT stock was purchased by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC and Calamos Advisors LLC. View Insider Buying and Selling for Fulgent Genetics.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLGT stock can currently be purchased for approximately $13.86.

Fulgent Genetics has a market capitalization of $259.32 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.

The official website for Fulgent Genetics is http://www.fulgentgenetics.com/.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]